Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

ation of SEROQUEL was administered twice-daily and escalated from 50 mg/day to 400 mg/day over a five-day period. The most common adverse events seen in the active treatment groups during the trial were somnolence and dizziness. The incidences of adverse events leading to discontinuation were low: 5.3%, 2.7%, and 2.5% in the SEROQUEL XR 400, 600, 800 mg/day groups; 4.9% in the immediate release SEROQUEL group; and 2.5% in the placebo group. Individual extrapyramidal symptoms (EPS)-related adverse events occurred in three patients or less in all treatment groups.(1,2)

    (+) Schizophrenic symptomatology measured on 30-item Positive and Negative

        Syndrome Scale (PANSS) scale. Each symptom was rated on a severity

        scale from 1-7. PANSS positive (7 items), negative (7 items), and

        general psychopathology (16 items) subscale scores were summarized to

        give the PANSS total score.(3)

About a poster presentation entitled: Efficacy of Once-Daily Extended Release

Quetiapine Fumarate in Patients with Acute Schizophrenia

This first analysis of Study 132 evaluated the efficacy of SEROQUEL XR versus placebo in patients with schizophrenia. The primary endpoint was the change from baseline to Day 42 in PANSS total score.(1)

After six weeks, the mean PANSS total score decreased significantly with SEROQUEL XR (400 mg: -24.8, p < 0.05; 600 mg: -30.9, p < 0.001; 800 mg: -31.3, p < 0.001) compared with placebo (-18.8). In addition, PANSS response rates for SEROQUEL XR (all doses) were significantly higher than for placebo (p < 0.05).(1)

About a poster presentation entitled: Efficacy of Once-Daily Extended Release

Quetiapine Fumarate across Symptom Domains in Schizophrenia

In this second analysis of Study 132, the efficacy of SEROQUEL XR was evaluated across a broad range of symptoms in schizophrenia, including positive and negative symptoms as well as symptoms of general psychopathology, aggr
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:7/9/2014)... MA -- Vasectomy was associated with a small increased ... advanced or lethal prostate cancer according to a new ... researchers found that the association remained even among men ... of lethal cancer cannot be explained by diagnostic bias. ... date to look at the link between vasectomy and ...
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... effective, long-term treatment for trigeminal neuralgia: a painful condition ... sclerosis (MS). Radiation is noninvasive and has less negative ... follow-up in a study of its kind presented October ... American Society for Radiation Oncology (ASTRO). Multiple ...
... HealthDay Reporter , MONDAY, Oct. 25 (HealthDay News) -- ... infants will start sleeping through the night between 2 and ... longer, however, is for the baby,s eight hours of slumber ... study. "The most rapid changes in infant sleep were ...
... cancer drug could be produced cheaply and sustainably using stem ... isolated and grown stem cells from a yew tree whose ... The development could enable the compound to be produced on ... Scientists and engineers behind the development say the ...
... reason many smokers struggle to quit. According to new ... history of anxiety disorders are less likely to quit ... Center for Tobacco Research and Intervention (UW-CTRI), offered free ... , While overall quit rates for the study were ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, Oct. ... with more than half of the segments in the heart,s main ... a new study shows. The good news? Other parts ... within three months or fewer after the run, the researchers found. ...
... HealthDay Reporter , SUNDAY, Oct. 24 (HealthDay News) -- Concussions ... Just last week, the National Football League announced it would ... result in head injuries. Now, a new 12-year study ... been sidelined significantly longer after concussions than they were in ...
Cached Medicine News:Health News:Radiation therapy improves painful condition associated with multiple sclerosis 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:Plant stem cells could be fruitful source of low-cost cancer drug 2Health News:Common anxiety disorders make it tougher to quit cigarettes 2Health News:Marathons Affect Heart, but Runners Bounce Back 2Health News:Marathons Affect Heart, but Runners Bounce Back 3Health News:NFL Players With Concussions Sidelined Longer: Study 2Health News:NFL Players With Concussions Sidelined Longer: Study 3
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
High temperature loop tip cautery....
Low temp, micro fine tip, patented Aaron RAM cauteries....
6 mm, 45 degree upwards, detachable....
Medicine Products: